Literature DB >> 32059982

NAFLD as a driver of chronic kidney disease.

Christopher D Byrne1, Giovanni Targher2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are worldwide public health problems, affecting up to 25-30% (NAFLD), and up to 10-15% (CKD) of the general population. Recently, it has also been established that there is a strong association between NAFLD and CKD, regardless of the presence of potential confounding diseases such as obesity, hypertension and type 2 diabetes. Since NAFLD and CKD are both common diseases that often occur alongside other metabolic conditions, such as type 2 diabetes or metabolic syndrome, elucidating the relative impact of NAFLD on the risk of incident CKD presents a substantial challenge for investigators working in this research field. A growing body of epidemiological evidence suggests that NAFLD is an independent risk factor for CKD and recent evidence also suggests that associated factors such as metabolic syndrome, dysbiosis, unhealthy diets, platelet activation and processes associated with ageing could also contribute mechanisms linking NAFLD and CKD. This narrative review provides an overview of the literature on: a) the evidence for an association and causal link between NAFLD and CKD and b) the underlying mechanisms by which NAFLD (and factors strongly linked with NAFLD) may increase the risk of developing CKD.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adipose tissue; CKD; Dysbiosis; Gut microbiota; Insulin resistance; Metabolic syndrome; Non-alcoholic fatty liver disease; Type 2 diabetes

Year:  2020        PMID: 32059982     DOI: 10.1016/j.jhep.2020.01.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  60 in total

Review 1.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

2.  Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.

Authors:  Xiaoyue Pan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

4.  Association between circulating cystatin C and hyperuricemia: a cross-sectional study.

Authors:  Yanjun Guo; Hangkai Huang; Yishu Chen; Chao Shen; Chengfu Xu
Journal:  Clin Rheumatol       Date:  2022-03-31       Impact factor: 2.980

5.  Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.

Authors:  Leonard Kaps; Christian Labenz; Peter R Galle; Julia Weinmann-Menke; Karel Kostev; Jörn M Schattenberg
Journal:  United European Gastroenterol J       Date:  2020-07-23       Impact factor: 4.623

6.  Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018.

Authors:  Yunlei Deng; Qianwen Zhao; Rong Gong
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-22       Impact factor: 3.168

7.  Mechanism of Huo-Xue-Qu-Yu Formula in Treating Nonalcoholic Hepatic Steatosis by Regulating Lipid Metabolism and Oxidative Stress in Rats.

Authors:  Bin Cheng; Ai-Zhen Zhou; Wen Ge; Xiao-Min Yao; Juan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-29       Impact factor: 2.629

Review 8.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

Review 9.  Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?

Authors:  Carolina M Perdomo; Nuria Garcia-Fernandez; Javier Escalada
Journal:  J Clin Med       Date:  2021-05-10       Impact factor: 4.241

10.  The Association between Decreased Kidney Function and FIB-4 Index Value, as Indirect Liver Fibrosis Indicator, in Middle-Aged and Older Subjects.

Authors:  Kazuko Kotoku; Ryoma Michishita; Takuro Matsuda; Shotaro Kawakami; Natsumi Morito; Yoshinari Uehara; Yasuki Higaki
Journal:  Int J Environ Res Public Health       Date:  2021-06-29       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.